Efficacy of evinacumab in homozygous familial hypercholesterolemia patients with null or non-null LDL-receptor mutations and on various background therapies
Amsterdam University Medical Centre, Amsterdam (Netherlands (The))
1
presentation
0
follower
7
more
presentations
in this session
Effects of empagliflozin on cardiac and vascular hemodynamic markers by subgroups of age, sex and hypertension in patients with T2DM and high CV risk: EMPA-reg outcome.
Monocyte chemoattractant protein-1 level and (-75)G/A polymorphism of APOA1 gene predict response and resistance to intensive statin therapy in very high cardiovascular risk patients.
Speaker:
Professor S. Villevalde (Saint Petersburg, RU)